Shu-Ying Liu1, Daryl J Wile2, Jessie Fanglu Fu3, Jason Valerio4, Elham Shahinfard4, Siobhan McCormick4, Rostom Mabrouk3, Nasim Vafai4, Jess McKenzie4, Nicole Neilson4, Alexandra Perez-Soriano4, Julieta E Arena4, Mariya Cherkasova4, Piu Chan5, Jing Zhang6, Cyrus P Zabetian7, Jan O Aasly8, Zbigniew K Wszolek9, Martin J McKeown4, Michael J Adam10, Thomas J Ruth11, Michael Schulzer4, Vesna Sossi3, A Jon Stoessl12. 1. Djavad Mowafaghian Centre for Brain Health, Pacific Parkinson's Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada; Department of Neurobiology, Neurology, and Geriatrics, Xuanwu Hospital Capital Medical University, Beijing, China. 2. University of British Columbia-Okanagan Southern Medical Program, Kelowna, BC, Canada. 3. Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada. 4. Djavad Mowafaghian Centre for Brain Health, Pacific Parkinson's Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada. 5. Department of Neurobiology, Neurology, and Geriatrics, Xuanwu Hospital Capital Medical University, Beijing, China. 6. Department of Pathology, University of Washington, Seattle, WA, USA. 7. Veterans Affairs Puget Sound Health Care System and Department of Neurology, University of Washington, Seattle, WA, USA. 8. Norwegian University of Science and Technology, Trondheim, Norway. 9. Mayo Clinic, Jacksonville, FL, USA. 10. Department of Chemistry, University of British Columbia, Vancouver, BC, Canada. 11. TRIUMF (Tri-University Meson Facility), Vancouver, BC, Canada. 12. Djavad Mowafaghian Centre for Brain Health, Pacific Parkinson's Research Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada. Electronic address: jstoessl@mail.ubc.ca.
Abstract
BACKGROUND: Markers of neuroinflammation are increased in some patients with LRRK2 Parkinson's disease compared with individuals with idiopathic Parkinson's disease, suggesting possible differences in disease pathogenesis. Previous PET studies have suggested amplified dopamine turnover and preserved serotonergic innervation in LRRK2 mutation carriers. We postulated that patients with LRRK2 mutations might show abnormalities of central cholinergic activity, even before the diagnosis of Parkinson's disease. METHODS: Between June, 2009, and December, 2015, we recruited participants from four movement disorder clinics in Canada, Norway, and the USA. Patients with Parkinson's disease were diagnosed by movement disorder neurologists on the basis of the UK Parkinson's Disease Society Brain Bank criteria. LRRK2 carrier status was confirmed by bidirectional Sanger sequencing. We used the PET tracer N-11C-methyl-piperidin-4-yl propionate to scan for acetylcholinesterase activity. The primary outcome measure was rate of acetylcholinesterase hydrolysis, calculated using the striatal input method. We compared acetylcholinesterase hydrolysis rates between groups using ANCOVA, with adjustment for age based on the results of linear regression analysis. FINDINGS: We recruited 14 patients with LRRK2 Parkinson's disease, 16 LRRK2 mutation carriers without Parkinson's disease, eight patients with idiopathic Parkinson's disease, and 11 healthy controls. We noted significant between-group differences in rates of acetylcholinesterase hydrolysis in cortical regions (average cortex p=0·009, default mode network-related regions p=0·006, limbic network-related regions p=0·020) and the thalamus (p=0·008). LRRK2 mutation carriers without Parkinson's disease had increased acetylcholinesterase hydrolysis rates compared with healthy controls in the cortex (average cortex, p=0·046). Patients with LRRK2 Parkinson's disease had significantly higher acetylcholinesterase activity in some cortical regions (average cortex p=0·043, default mode network-related regions p=0·021) and the thalamus (thalamus p=0·004) compared with individuals with idiopathic disease. Acetylcholinesterase hydrolysis rates in healthy controls were correlated inversely with age. INTERPRETATION: LRRK2 mutations are associated with significantly increased cholinergic activity in the brain in mutation carriers without Parkinson's disease compared with healthy controls and in LRRK2 mutation carriers with Parkinson's disease compared with individuals with idiopathic disease. Changes in cholinergic activity might represent early and sustained attempts to compensate for LRRK2-related dysfunction, or alteration of acetylcholinesterase in non-neuronal cells. FUNDING: Michael J Fox Foundation, National Institutes of Health, and Pacific Alzheimer Research Foundation.
BACKGROUND: Markers of neuroinflammation are increased in some patients with LRRK2 Parkinson's disease compared with individuals with idiopathic Parkinson's disease, suggesting possible differences in disease pathogenesis. Previous PET studies have suggested amplified dopamine turnover and preserved serotonergic innervation in LRRK2 mutation carriers. We postulated that patients with LRRK2 mutations might show abnormalities of central cholinergic activity, even before the diagnosis of Parkinson's disease. METHODS: Between June, 2009, and December, 2015, we recruited participants from four movement disorder clinics in Canada, Norway, and the USA. Patients with Parkinson's disease were diagnosed by movement disorder neurologists on the basis of the UK Parkinson's Disease Society Brain Bank criteria. LRRK2 carrier status was confirmed by bidirectional Sanger sequencing. We used the PET tracer N-11C-methyl-piperidin-4-yl propionate to scan for acetylcholinesterase activity. The primary outcome measure was rate of acetylcholinesterase hydrolysis, calculated using the striatal input method. We compared acetylcholinesterase hydrolysis rates between groups using ANCOVA, with adjustment for age based on the results of linear regression analysis. FINDINGS: We recruited 14 patients with LRRK2 Parkinson's disease, 16 LRRK2 mutation carriers without Parkinson's disease, eight patients with idiopathic Parkinson's disease, and 11 healthy controls. We noted significant between-group differences in rates of acetylcholinesterase hydrolysis in cortical regions (average cortex p=0·009, default mode network-related regions p=0·006, limbic network-related regions p=0·020) and the thalamus (p=0·008). LRRK2 mutation carriers without Parkinson's disease had increased acetylcholinesterase hydrolysis rates compared with healthy controls in the cortex (average cortex, p=0·046). Patients with LRRK2 Parkinson's disease had significantly higher acetylcholinesterase activity in some cortical regions (average cortex p=0·043, default mode network-related regions p=0·021) and the thalamus (thalamus p=0·004) compared with individuals with idiopathic disease. Acetylcholinesterase hydrolysis rates in healthy controls were correlated inversely with age. INTERPRETATION:LRRK2 mutations are associated with significantly increased cholinergic activity in the brain in mutation carriers without Parkinson's disease compared with healthy controls and in LRRK2 mutation carriers with Parkinson's disease compared with individuals with idiopathic disease. Changes in cholinergic activity might represent early and sustained attempts to compensate for LRRK2-related dysfunction, or alteration of acetylcholinesterase in non-neuronal cells. FUNDING: Michael J Fox Foundation, National Institutes of Health, and Pacific Alzheimer Research Foundation.
Authors: Nis Pedersen Jørgensen; Aage K O Alstrup; Frank V Mortensen; Karoline Knudsen; Steen Jakobsen; Line Bille Madsen; Dirk Bender; Peter Breining; Mikkel Steen Petersen; Mariane Høgsberg Schleimann; Frederik Dagnæs-Hansen; Lars C Gormsen; Per Borghammer Journal: Eur J Nucl Med Mol Imaging Date: 2016-10-26 Impact factor: 9.236
Authors: S Nagatsuka Si; K Fukushi; H Shinotoh; H Namba; M Iyo; N Tanaka; A Aotsuka; T Ota; S Tanada; T Irie Journal: J Cereb Blood Flow Metab Date: 2001-11 Impact factor: 6.200
Authors: Avner Thaler; Anat Mirelman; Rick C Helmich; Bart F L van Nuenen; Keren Rosenberg-Katz; Tanya Gurevich; Avi Orr-Urtreger; Karen Marder; Susan Bressman; Bastiaan R Bloem; Nir Giladi; Talma Hendler Journal: Cortex Date: 2013-01-07 Impact factor: 4.027
Authors: Roy N Alcalay; Anat Mirelman; Rachel Saunders-Pullman; Ming-X Tang; Helen Mejia Santana; Deborah Raymond; Ernest Roos; Martha Orbe-Reilly; Tanya Gurevich; Anat Bar Shira; Mali Gana Weisz; Kira Yasinovsky; Maayan Zalis; Avner Thaler; Andres Deik; Matthew James Barrett; Jose Cabassa; Mark Groves; Ann L Hunt; Naomi Lubarr; Marta San Luciano; Joan Miravite; Christina Palmese; Rivka Sachdev; Harini Sarva; Lawrence Severt; Vicki Shanker; Matthew Carrington Swan; Jeannie Soto-Valencia; Brooke Johannes; Robert Ortega; Stanley Fahn; Lucien Cote; Cheryl Waters; Pietro Mazzoni; Blair Ford; Elan Louis; Oren Levy; Llency Rosado; Diana Ruiz; Tsvyatko Dorovski; Michael Pauciulo; William Nichols; Avi Orr-Urtreger; Laurie Ozelius; Lorraine Clark; Nir Giladi; Susan Bressman; Karen S Marder Journal: Mov Disord Date: 2013-10-15 Impact factor: 10.338
Authors: Claudia Carricarte Naranjo; Connie Marras; Naomi P Visanji; David J Cornforth; Lazaro Sanchez-Rodriguez; Birgitt Schüle; Samuel M Goldman; Mario Estévez; Phyllis K Stein; Anthony E Lang; Herbert F Jelinek; Andrés Machado Journal: Clin Auton Res Date: 2019-08-23 Impact factor: 4.435
Authors: Katharina A Schindlbeck; An Vo; Nha Nguyen; Chris C Tang; Martin Niethammer; Vijay Dhawan; Vicky Brandt; Rachel Saunders-Pullman; Susan B Bressman; David Eidelberg Journal: Cereb Cortex Date: 2020-05-14 Impact factor: 5.357
Authors: Nicolaas I Bohnen; Alison J Yarnall; Rimona S Weil; Elena Moro; Mark S Moehle; Per Borghammer; Marc-André Bedard; Roger L Albin Journal: Lancet Neurol Date: 2022-02-04 Impact factor: 44.182
Authors: Roger L Albin; Sygrid van der Zee; Teus van Laar; Martin Sarter; Cindy Lustig; Martijn L T M Muller; Nicolaas I Bohnen Journal: Prog Brain Res Date: 2022-02-04 Impact factor: 2.453
Authors: Trina Mitchell; Stéphane Lehéricy; Shannon Y Chiu; Antonio P Strafella; A Jon Stoessl; David E Vaillancourt Journal: JAMA Neurol Date: 2021-10-01 Impact factor: 29.907
Authors: Daniela Berg; Per Borghammer; Seyed-Mohammad Fereshtehnejad; Sebastian Heinzel; Jacob Horsager; Eva Schaeffer; Ronald B Postuma Journal: Nat Rev Neurol Date: 2021-04-20 Impact factor: 42.937